According to CNBC TV18 and Business Standard, Abbott India delivered strong first-quarter results for FY27, with consolidated net profit rising 17.12% year-on-year to ₹429 crore compared to ₹366 crore in the same quarter last year. Consolidated revenue grew 4.3% year-on-year to ₹1,813.6 crore, up from ₹1,738.4 crore in Q1 FY26. The company's EBITDA increased 17.3% to ₹522.4 crore, with the margin expanding significantly to 28.81% from 25.63% in the previous year. This performance demonstrates the company's operational efficiency and ability to maintain profitability growth despite modest revenue expansion.
As reported by Moneycontrol, for the year-ending March 2026, Abbott India reported standalone sales of ₹6,929 crore, representing an increase from ₹6,409 crore in the year-ending March 2025. Total income for the year-ending March 2026 stood at ₹7,217 crore, up from ₹6,684 crore in the previous year. The company's net profit also saw a significant rise, reaching ₹1,552 crore for the year-ending March 2026, compared to ₹1,414 crore in March 2025. The company's Basic EPS for the year-ending March 2026 was ₹730.36, with a Diluted EPS of ₹730.36. Over five years, from March 2022 to March 2026, sales grew from ₹4,919 crore to ₹6,929 crore, reflecting consistent operational expansion, while net profit almost doubled from ₹798 crore in March 2022 to ₹1,552 crore in March 2026.
According to CNBC TV18, Abbott India announced significant leadership changes effective August 12, 2026. Munir Shaikh, non-executive director, has stepped down as Chairman of the Board of Directors with effect from the close of business hours on August 12, 2026. Following the recommendation of the Nomination and Remuneration Committee and in accordance with the company's Articles of Association, Sudarshan Jain, an independent director, has been appointed Chairman of the Board of Directors with effect from August 13, 2026. This transition reflects the company's governance structure and succession planning processes.
According to Moneycontrol, shares of Abbott India declined by 2.03% to ₹27,570.00 on Thursday, August 13, 2026, placing the stock among the top losers on the Nifty Midcap 150 index, of which it is a constituent. The stock continues to demonstrate strong market performance and remains a constituent of the Nifty Midcap 150 index. The positive movement reflects investor confidence in the company's financial trajectory and operational efficiency, though recent trading activity shows some profit-taking after the strong quarterly announcement. With the stock trading at ₹27,570.00, Abbott India's performance reflects recent market movements and its solid financial standing, supported by consistent growth and attractive shareholder returns.
According to Moneycontrol, Abbott India's Board of Directors convened on August 12, 2026, to review and approve the unaudited financial results for the quarter ended June 30, 2026. The company declared a final dividend of ₹525.00 per share and a special dividend of ₹131.00 per share, both effective July 24, 2026. The stock has a history of bonus issues, with the latest being a 1:1 bonus share issue announced on August 10, 1998. The company maintains a debt-free operation with a Debt to Equity ratio of 0.00, indicating strong financial health. Key financial ratios show healthy metrics with Return on Networth/Equity at 32.50% and ROCE at 41.87% in March 2026.
